TNFRSF8 antibody (PE)

Catalog No. ABIN2663333

Product Details anti-TNFRSF8 Antibody (PE)

Target: TNFRSF8 (Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNFRSF8 antibody is conjugated to PE

Application: Immunofluorescence (IF), Western Blotting (WB)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: BY88

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TNFRSF8

Target: TNFRSF8 (Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8))

Alternative Name: CD30 (TNFRSF8 Products)

Synonyms: CD30 antibody, D1S166E antibody, Ki-1 antibody, Cd30 antibody, Ki antibody, TNFRSF8 antibody, TNF receptor superfamily member 8 antibody, tumor necrosis factor receptor superfamily, member 8 antibody, TNFRSF8 antibody, Tnfrsf8 antibody

Background: CD30, also known as Ki-1 antigen, lymphoid activation antigen CD30, and tumor necrosis factor receptor superfamily member 8 is a type I transmembrane receptor that contains four TNF receptor domains with an approximate molecular weight of 64 kD. CD30 is highly expressed on Hodgkins and Reed-Sternberg cells as well as activated, but not resting, T and B cells. CD30 has been shown to interact with a number of proteins including TRAF1, TRAF2, TRAF3, TRAF5, NPM-ALK, TRAF-interacting protein, and CD30 ligand (CD153). Signaling through CD30 is thought to limit the proliferative potential of autoreactive CD8 effector T cells and protect against autoimmunity.